The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Proportion of patients in south London with first-episode psychosis attributable to use of high potency cannabis: a case-control study
Open accessAbstract
BACKGROUND: The risk of individuals having adverse effects from drug use (eg, alcohol) generally depends on the frequency of use and potency of the drug used. We aimed to investigate how frequent use of skunk-like (high-potency) cannabis in south London affected the association between cannabis and psychotic disorders. METHODS: We applied adjusted logistic regression models to data from patients aged 18-65 years presenting to South London and Maudsley NHS Foundation Trust with first-episode psychosis and population controls recruited from the same area of south London (UK) to estimate the effect of the frequency of use, and type of cannabis used on the risk of psychotic disorders. We then calculated the proportion of new cases of psychosis attributable to different types of cannabis use in south London. FINDINGS: Between May 1, 2005, and May 31, 2011, we obtained data from 410 patients with first-episode psychosis and 370 population controls. The risk of individuals having a psychotic disorder showed a roughly three-times increase in users of skunk-like cannabis compared with those who never used cannabis (adjusted odds ratio [OR] 2·92, 95% CI 1·52-3·45, p=0·001). Use of skunk-like cannabis every day conferred the highest risk of psychotic disorders compared with no use of cannabis (adjusted OR 5·4, 95% CI 2·81-11·31, p=0·002). The population attributable fraction of first-episode psychosis for skunk use for our geographical area was 24% (95% CI 17-31), possibly because of the high prevalence of use of high-potency cannabis (218 [53%] of 410 patients) in our study. INTERPRETATION: The ready availability of high potency cannabis in south London might have resulted in a greater proportion of first onset psychosis cases being attributed to cannabis use than in previous studies. FUNDING: UK National Institute of Health Research (NIHR) Specialist Biomedical Research Centre for Mental Health, SLaM and the Institute of Psychiatry at King's College London, Psychiatry Research Trust, Maudsley Charity Research Fund, and th European Community's Seventh Framework Program grant (agreement No. HEALTH-F2-2009-241909 [Project EU-GEI]).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A recent case-control study found that whilst 'skunk' cannabis (high THC:CBD) was associated with risk of a psychotic episode, 'hash' cannabis (low THC:CBD) was not (48).”
From Association Between Cannabis and Psychosis: Epidemiologic Evidence (2016) · cites this paper as [48]
In the citing paper
“or in those who use particularly potent strains of cannabis (48).”
From Association Between Cannabis and Psychosis: Epidemiologic Evidence (2016) · cites this paper as [48]
In the citing paper
“Similarly, the combination of daily use with high potency cannabis confers almost double the odds of developing psychosis (Di Forti et al., 2015).”
From Risk-thresholds for the association between frequency of cannabis use and the development of psychosis: a systematic review and meta-analysis (2023) · cites this paper as Di Forti et al., 2015
In the citing paper
“Beyond the role of use frequency, epidemiological data have identified the use of high potency cannabis, early age-of-use onset (e.g. pre-25), childhood trauma, and concurrent other substance use as contributing factors to psychosis development (Di Forti et al., 2015; Hall & Lynskey, 2020; Kiburi et al., 2021; van der Steur et al., 2020).”
From Risk-thresholds for the association between frequency of cannabis use and the development of psychosis: a systematic review and meta-analysis (2023) · cites this paper as Di Forti et al., 2015
In the citing paper
“While more frequent cannabis use to be appears associated with an elevated risk of psychosis, this risk is likely further influenced by other risk-factors (e.g. genetics, family history, cannabis potency) that require additional consideration for and incorporation into prevention messaging beyond mere frequency-of-use factors”
From Risk-thresholds for the association between frequency of cannabis use and the development of psychosis: a systematic review and meta-analysis (2023) · cites this paper as Di Forti et al., 2015
Citations
Cites
SCAN: Schedules fonr Clinical Assessment in Neuropsychiatry
Wing, J. K. (1990) · Archives of General Psychiatry · doi:10.1001/archpsyc.1990.01810180089012 · Cited by 2,517
Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review.
Moore, T. H., Zammit, S., Lingford-Hughes, A., Barnes, T. R., Jones, P. B., Burke, M., & Lewis, G. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61162-3 · Cited by 2,224
Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia
Leweke, F. M., Piomelli, D., Pahlisch, F., Muhl, D., Gerth, C. W., Hoyer, C., Klosterkötter, J., Hellmich, M., & Koethe, D. (2012) · Translational Psychiatry · doi:10.1038/tp.2012.15 · Cited by 1,059
D'Souza, D. C., Perry, E., MacDougall, L., Ammerman, Y., Cooper, T., Wu, Y.-T., Braley, G., Gueorguieva, R., & Krystal, J. H. (2004) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300496 · Cited by 1,024
Cannabis use and psychosis: A longitudinal population-based study
van Os, J. (2002) · American Journal of Epidemiology · doi:10.1093/aje/kwf043 · Cited by 928
Causal association between cannabis and psychosis: examination of the evidence
Arseneault, L., Cannon, M., Witton, J., & Murray, R. M. (2004) · British Journal of Psychiatry · doi:10.1192/bjp.184.2.110 · Cited by 913
Self-citationHenquet, C., Krabbendam, L., Spauwen, J., Kaplan, C., Lieb, R., Wittchen, H.-U., & van Os, J. (2005) · BMJ · doi:10.1136/bmj.38267.664086.63 · Cited by 765
High-potency cannabis and the risk of psychosis
Di Forti, M., Morgan, C., Dazzan, P., Pariante, C., Mondelli, V., Marques, T. R., Handley, R., Luzi, S., Russo, M., Paparelli, A., et al. (2009) · British Journal of Psychiatry · doi:10.1192/bjp.bp.109.064220 · Cited by 567
Self-citationPsychosis Screening Questionnaire
Bebbington, P., & Nayani, T. (2014) · PsycTESTS Dataset · doi:10.1037/t30040-000 · Cited by 541
Cited by
Prevalence of marijuana use disorders in the United States between 2001-2002 and 2012-2013.
Hasin, D. S., Saha, T. D., Kerridge, B. T., Goldstein, R. B., Chou, S. P., Zhang, H., Jung, J., Pickering, R. P., Ruan, W. J., Smith, S. M., et al. (2015) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2015.1858 · Cited by 1,086
Di Forti, M., Quattrone, D., Freeman, T. P., Tripoli, G., Gayer-Anderson, C., Quigley, H., Rodriguez, V., Jongsma, H. E., Ferraro, L., La Cascia, C., et al. (2019) · The Lancet Psychiatry · doi:10.1016/s2215-0366(19)30048-3 · Cited by 875
Self-citationEffects of Cannabis Use on Human Behavior, Including Cognition, Motivation, and Psychosis: A Review
Volkow, N. D., Swanson, J. M., Evins, A. E., DeLisi, L. E., Meier, M. H., Gonzalez, R., Bloomfield, M. A. P., Curran, H. V., & Baler, R. (2016) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2015.3278 · Cited by 867
Acute and Chronic Effects of Cannabinoids on Human Cognition—A Systematic Review
Broyd, S. J., van Hell, H. H., Beale, C., Yücel, M., & Solowij, N. (2016) · Biological Psychiatry · doi:10.1016/j.biopsych.2015.12.002 · Cited by 674
The Role of Genes, Stress, and Dopamine in the Development of Schizophrenia
Howes, O. D., McCutcheon, R., Owen, M. J., & Murray, R. M. (2017) · Biological Psychiatry · doi:10.1016/j.biopsych.2016.07.014 · Cited by 601
Self-citation
Metadata
- Authors
- Di Forti, M., Marconi, A., Carra, E., Fraietta, S., Trotta, A., Bonomo, M., Bianconi, F., Gardner-Sood, P., O'Connor, J., Russo, M., Stilo, S. A., Marques, T. R., Mondelli, V., Dazzan, P., Pariante, C., David, A. S., Gaughran, F., Atakan, Z., Iyegbe, C., Powell, J., Morgan, C., Lynskey, M., & Murray, R. M.
- Affiliations
- King's College London (GB)
- Icahn School of Medicine at Mount Sinai (US)
- ORCID
- Venue
- The Lancet Psychiatry
- Publisher
- Elsevier BV
- Published
- 2015-03
- Volume
- 2
- Issue
- 3
- Pages
- 233-238
- ISSN
- 2215-0366 (ISSN-L)
- OpenAlex
- W2144625250
- Cited by
- 588
- References
- 27
- Citations by year
- 2026: 19 · 2025: 37 · 2024: 50 · 2023: 32 · 2022: 40 · 2021: 48 · 2020: 69 · 2019: 64 · 2018: 65 · 2017: 53 · 2016: 54 · 2015: 57
- FWCI
- 54.58
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor)
- Locations
- The Lancet Psychiatry (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
- Research Portal (King's College London) (submittedVersion, other-oa)
- Funders
- National Institute for Health and Care Research (CL-2008-17-005, NF-SI-0510-10129, CL-2012-17-004, RP-PG-0606-1049)
- Academy of Medical Sciences (AMS-SGCL5-Mondelli)
- Medical Research Council (MR/M008436/1)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Cannabis and Cannabinoid Research
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Forensic Toxicology and Drug Analysis
- Keywords
- first-episode psychosis, high-potency cannabis, cannabis use frequency, psychosis, population attributable fraction, South London, cannabis availability, psychosis risk
- MeSH terms
- Adolescent, Adult, Aged, Cannabis, Female, Humans, London, Male, Middle Aged, Psychotic Disorders, Risk Factors, Case-Control Studies, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Proportion of patients in south London with first-episode psychosis attributable to use of high potency cannabis: a case-control study. https://app.cochat.ai/papers/10.1016/s2215-0366(14)00117-5
- The paper
- Di Forti, M., Marconi, A., Carra, E., Fraietta, S., Trotta, A., Bonomo, M., Bianconi, F., Gardner-Sood, P., O'Connor, J., Russo, M., Stilo, S. A., Marques, T. R., Mondelli, V., Dazzan, P., Pariante, C., David, A. S., Gaughran, F., Atakan, Z., Iyegbe, C., . . . Murray, R. M. (2015). Proportion of patients in south London with first-episode psychosis attributable to use of high potency cannabis: a case-control study. The Lancet Psychiatry. https://doi.org/10.1016/s2215-0366(14)00117-5
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.